Fatty liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD), affects approximately 25% of US adults and is closely linked to obesity
Blinded allocation, centralized measurement of renal endpoints, and high retention rates support confidence in directionality of effect, while limitations arise primarily from study duration, sample size, and surrogate endpoints (albuminuria, eGFR slope)
These combined effects lower estimated 10-year cardiovascular risk by 35-40% based on improved risk factors, though actual event reduction hasn't been proven yet
Amita, for giving my mother a new lease on life
Reach: 60 - 100 Million people (The Affluent India cohort)